Doxefazepam is a new fluorinated benzodiazepine which was shown to have potent sedative effects in animals and marked hypnotic properties in man. The hypnotic efficacy of 20 mg doxefazepam was evaluated on laboratory sleep of eight insomniacs with early, 1-week and 2-week nightly administration. The withdrawal effects were evaluated during three consecutive nights after drug interruption. The results of the study indicate that doxefazepam is an effective benzodiazepine hypnotic which does not develop a significant tolerance with nightly usage for two weeks. It exerts its hypnotic action mainly by increasing stage 2 without significantly suppressing slow wave sleep. It has only slight effects on REM sleep. The maximal hypnotic efficacy of doxefazepam is present at the onset of treatment and, after drug interruption, the sleep parameters return toward baseline levels without evidence of carry-over effects, rebound in somnia and REM rebound. No early morning insomnia was observed after nightly treatment for two weeks. These data suggest that doxefazepam is a short-acting benzodiazepine hypnotic in agreement with the results of a preliminary pharmacokinetic study.
|Number of pages||10|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1985|
ASJC Scopus subject areas